Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 33 | 2024 | 1866 | 3.840 |
Why?
|
Pulmonary Embolism | 38 | 2024 | 2566 | 3.500 |
Why?
|
Anticoagulants | 36 | 2023 | 4813 | 1.820 |
Why?
|
Venous Thrombosis | 12 | 2024 | 1303 | 1.670 |
Why?
|
Blood Coagulation | 8 | 2020 | 1154 | 1.270 |
Why?
|
Warfarin | 6 | 2023 | 1483 | 1.270 |
Why?
|
Thrombosis | 8 | 2023 | 2942 | 1.210 |
Why?
|
Heparin | 10 | 2022 | 1633 | 1.170 |
Why?
|
Patient Care Team | 9 | 2020 | 2523 | 1.120 |
Why?
|
Hemorrhage | 22 | 2023 | 3425 | 1.030 |
Why?
|
Thrombolytic Therapy | 10 | 2024 | 2062 | 0.760 |
Why?
|
Thrombophilia | 2 | 2021 | 305 | 0.760 |
Why?
|
Administration, Oral | 12 | 2023 | 4013 | 0.730 |
Why?
|
African Swine Fever | 1 | 2020 | 7 | 0.710 |
Why?
|
Blood Coagulation Factors | 4 | 2020 | 365 | 0.670 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2021 | 422 | 0.640 |
Why?
|
Heparin, Low-Molecular-Weight | 5 | 2023 | 344 | 0.620 |
Why?
|
Antithrombins | 1 | 2021 | 294 | 0.600 |
Why?
|
Aftercare | 2 | 2020 | 913 | 0.550 |
Why?
|
Neoplasms | 19 | 2024 | 22158 | 0.500 |
Why?
|
Pyridones | 2 | 2020 | 808 | 0.490 |
Why?
|
Standard of Care | 1 | 2018 | 550 | 0.470 |
Why?
|
Blood Coagulation Disorders | 3 | 2021 | 350 | 0.440 |
Why?
|
Flank Pain | 1 | 2013 | 43 | 0.430 |
Why?
|
Renal Veins | 1 | 2013 | 102 | 0.430 |
Why?
|
Pyrazoles | 3 | 2020 | 2007 | 0.410 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1461 | 0.390 |
Why?
|
Obesity, Morbid | 1 | 2023 | 1277 | 0.390 |
Why?
|
Emergency Service, Hospital | 7 | 2024 | 7872 | 0.350 |
Why?
|
Partial Thromboplastin Time | 2 | 2021 | 203 | 0.330 |
Why?
|
Patient Compliance | 1 | 2020 | 2690 | 0.330 |
Why?
|
Anxiety | 1 | 2024 | 4571 | 0.330 |
Why?
|
Hospitalization | 6 | 2024 | 10715 | 0.330 |
Why?
|
Humans | 104 | 2024 | 761326 | 0.320 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3080 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3200 | 0.310 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7389 | 0.300 |
Why?
|
Peptide Fragments | 1 | 2020 | 5114 | 0.300 |
Why?
|
Consensus | 5 | 2024 | 3122 | 0.290 |
Why?
|
Thromboembolism | 3 | 2021 | 996 | 0.290 |
Why?
|
Catheterization | 2 | 2020 | 1432 | 0.290 |
Why?
|
Factor VIIa | 1 | 2008 | 103 | 0.280 |
Why?
|
Hospital Rapid Response Team | 2 | 2018 | 54 | 0.280 |
Why?
|
Retrospective Studies | 22 | 2024 | 80575 | 0.270 |
Why?
|
Clinical Protocols | 4 | 2020 | 1440 | 0.260 |
Why?
|
Myeloproliferative Disorders | 2 | 2022 | 613 | 0.260 |
Why?
|
Middle Aged | 44 | 2024 | 220774 | 0.260 |
Why?
|
Risk Factors | 27 | 2024 | 74152 | 0.260 |
Why?
|
Critical Illness | 5 | 2021 | 2722 | 0.250 |
Why?
|
Pulmonary Artery | 3 | 2021 | 1938 | 0.250 |
Why?
|
Stress, Physiological | 1 | 2012 | 1403 | 0.250 |
Why?
|
Delivery of Health Care | 4 | 2024 | 5334 | 0.240 |
Why?
|
Female | 58 | 2024 | 392485 | 0.240 |
Why?
|
Depression | 1 | 2024 | 8122 | 0.230 |
Why?
|
Aged | 36 | 2024 | 169179 | 0.230 |
Why?
|
C-Reactive Protein | 4 | 2024 | 3824 | 0.220 |
Why?
|
Hematopoietic Cell Growth Factors | 2 | 2022 | 98 | 0.220 |
Why?
|
Male | 49 | 2024 | 360621 | 0.210 |
Why?
|
Acute Disease | 9 | 2024 | 7238 | 0.200 |
Why?
|
Risk Assessment | 13 | 2024 | 23981 | 0.190 |
Why?
|
Micropore Filters | 1 | 2020 | 22 | 0.180 |
Why?
|
Platelet Count | 2 | 2020 | 781 | 0.180 |
Why?
|
Ceruloplasmin | 1 | 2020 | 57 | 0.180 |
Why?
|
Iron Metabolism Disorders | 1 | 2020 | 24 | 0.180 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 97 | 0.180 |
Why?
|
Thrombocytopenia | 4 | 2020 | 1179 | 0.180 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3687 | 0.180 |
Why?
|
Pipecolic Acids | 1 | 2021 | 77 | 0.180 |
Why?
|
Drug Antagonism | 1 | 2019 | 51 | 0.170 |
Why?
|
Prothrombin | 1 | 2020 | 191 | 0.170 |
Why?
|
Endothelial Cells | 1 | 2012 | 3543 | 0.170 |
Why?
|
Adult | 30 | 2024 | 221122 | 0.170 |
Why?
|
Hirudins | 1 | 2021 | 179 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.170 |
Why?
|
von Willebrand Disease, Type 1 | 1 | 2019 | 5 | 0.170 |
Why?
|
Fibrinolytic Agents | 4 | 2023 | 2082 | 0.160 |
Why?
|
Probability | 1 | 2024 | 2478 | 0.160 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2019 | 87 | 0.160 |
Why?
|
Biological Specimen Banks | 1 | 2024 | 783 | 0.160 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6525 | 0.150 |
Why?
|
Ultrasonography, Doppler | 1 | 2020 | 461 | 0.150 |
Why?
|
Outpatients | 4 | 2018 | 1596 | 0.150 |
Why?
|
Drug Monitoring | 2 | 2021 | 961 | 0.150 |
Why?
|
Ambulatory Care | 2 | 2020 | 2775 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
Pyrrolidinones | 1 | 2018 | 116 | 0.150 |
Why?
|
Risk Adjustment | 1 | 2021 | 600 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11735 | 0.140 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 95 | 0.140 |
Why?
|
Thrombectomy | 3 | 2017 | 705 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12144 | 0.140 |
Why?
|
Hospitals, University | 1 | 2019 | 564 | 0.140 |
Why?
|
Dextrocardia | 1 | 2016 | 37 | 0.140 |
Why?
|
Antiphospholipid Syndrome | 1 | 2018 | 165 | 0.140 |
Why?
|
Emergency Treatment | 2 | 2018 | 496 | 0.140 |
Why?
|
Treatment Outcome | 14 | 2024 | 64645 | 0.140 |
Why?
|
Anemia | 3 | 2022 | 1508 | 0.140 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5146 | 0.130 |
Why?
|
Amygdala | 1 | 2024 | 1353 | 0.130 |
Why?
|
Heart Rate | 2 | 2024 | 4197 | 0.130 |
Why?
|
Plasma | 1 | 2019 | 586 | 0.130 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 242 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1164 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 1 | 2024 | 1175 | 0.120 |
Why?
|
History, 19th Century | 1 | 2017 | 720 | 0.120 |
Why?
|
Leukemia | 1 | 2022 | 1523 | 0.120 |
Why?
|
Patient Transfer | 1 | 2021 | 793 | 0.110 |
Why?
|
Ultrasonography | 2 | 2020 | 5970 | 0.110 |
Why?
|
Mass Screening | 1 | 2010 | 5428 | 0.110 |
Why?
|
China | 1 | 2020 | 2348 | 0.110 |
Why?
|
Incidence | 3 | 2024 | 21336 | 0.110 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15499 | 0.110 |
Why?
|
Aorta | 1 | 2021 | 2042 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4850 | 0.110 |
Why?
|
Aged, 80 and over | 10 | 2024 | 58946 | 0.100 |
Why?
|
Hospital Mortality | 2 | 2024 | 5291 | 0.100 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2578 | 0.100 |
Why?
|
Drug Interactions | 1 | 2017 | 1415 | 0.100 |
Why?
|
ROC Curve | 1 | 2020 | 3572 | 0.100 |
Why?
|
Echocardiography | 3 | 2020 | 4991 | 0.100 |
Why?
|
Quinolines | 1 | 2018 | 764 | 0.100 |
Why?
|
Lower Extremity | 1 | 2020 | 1201 | 0.100 |
Why?
|
Obesity | 3 | 2023 | 12934 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2019 | 1196 | 0.100 |
Why?
|
Antibodies, Antinuclear | 1 | 2013 | 344 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5303 | 0.100 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2013 | 147 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1438 | 0.100 |
Why?
|
Medical Oncology | 2 | 2020 | 2321 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1212 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1580 | 0.100 |
Why?
|
Neurodegenerative Diseases | 1 | 2020 | 1086 | 0.100 |
Why?
|
History, 21st Century | 1 | 2017 | 1567 | 0.090 |
Why?
|
Thromboplastin | 1 | 2012 | 286 | 0.090 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2016 | 628 | 0.090 |
Why?
|
Intensive Care Units | 3 | 2021 | 3744 | 0.090 |
Why?
|
Hypotension | 1 | 2016 | 879 | 0.090 |
Why?
|
Inpatients | 2 | 2021 | 2548 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1762 | 0.090 |
Why?
|
Pandemics | 5 | 2021 | 8635 | 0.090 |
Why?
|
Enoxaparin | 1 | 2012 | 391 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1813 | 0.090 |
Why?
|
Swine | 1 | 2020 | 5915 | 0.090 |
Why?
|
Patient Readmission | 1 | 2024 | 3267 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1896 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1256 | 0.080 |
Why?
|
Massachusetts | 2 | 2020 | 8837 | 0.080 |
Why?
|
Factor Xa | 2 | 2020 | 167 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2770 | 0.080 |
Why?
|
Vena Cava Filters | 3 | 2017 | 261 | 0.080 |
Why?
|
Review Literature as Topic | 2 | 2008 | 347 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2021 | 3816 | 0.080 |
Why?
|
Stress, Psychological | 1 | 2024 | 4477 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3244 | 0.080 |
Why?
|
Heart Failure | 2 | 2022 | 11672 | 0.080 |
Why?
|
Cohort Studies | 8 | 2024 | 41440 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2018 | 2093 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3597 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 885 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3335 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2024 | 4579 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1605 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13333 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2020 | 3441 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13635 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2012 | 2712 | 0.060 |
Why?
|
Resource Allocation | 1 | 2008 | 350 | 0.060 |
Why?
|
Shock | 1 | 2008 | 314 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12972 | 0.060 |
Why?
|
Dexamethasone | 1 | 2012 | 1946 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14665 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14597 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9275 | 0.060 |
Why?
|
Recurrence | 3 | 2023 | 8470 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5127 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 10203 | 0.050 |
Why?
|
Evidence-Based Practice | 1 | 2008 | 495 | 0.050 |
Why?
|
Safety | 1 | 2008 | 1150 | 0.050 |
Why?
|
Genotype | 2 | 2021 | 12982 | 0.050 |
Why?
|
Pyridines | 1 | 2014 | 2870 | 0.050 |
Why?
|
Registries | 3 | 2024 | 8223 | 0.050 |
Why?
|
Lung | 1 | 2021 | 9994 | 0.050 |
Why?
|
Sex Characteristics | 2 | 2023 | 2637 | 0.050 |
Why?
|
Germany | 1 | 2024 | 875 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 4 | 2024 | 20555 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2013 | 2163 | 0.050 |
Why?
|
United States | 7 | 2024 | 72317 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11070 | 0.050 |
Why?
|
Chelation Therapy | 1 | 2020 | 77 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9749 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39108 | 0.040 |
Why?
|
Cause of Death | 2 | 2021 | 3685 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 201 | 0.040 |
Why?
|
Skin Diseases | 1 | 2008 | 1092 | 0.040 |
Why?
|
Catheterization, Central Venous | 1 | 2005 | 527 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14025 | 0.040 |
Why?
|
Respiration, Artificial | 2 | 2021 | 2625 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17872 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 105 | 0.040 |
Why?
|
Mitral Valve | 1 | 2008 | 1471 | 0.040 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 144 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
Prospective Studies | 4 | 2020 | 54405 | 0.040 |
Why?
|
Sex Factors | 2 | 2024 | 10551 | 0.040 |
Why?
|
Unconsciousness | 1 | 2020 | 250 | 0.040 |
Why?
|
Iodine | 1 | 2021 | 288 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2021 | 743 | 0.040 |
Why?
|
Patient Care Management | 1 | 2021 | 302 | 0.040 |
Why?
|
Equipment Failure Analysis | 1 | 2020 | 847 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 709 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18401 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 271 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2898 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 597 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2017 | 154 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3420 | 0.040 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2008 | 1555 | 0.040 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2017 | 187 | 0.040 |
Why?
|
Expert Testimony | 1 | 2019 | 363 | 0.040 |
Why?
|
North America | 1 | 2020 | 1275 | 0.030 |
Why?
|
Length of Stay | 2 | 2021 | 6422 | 0.030 |
Why?
|
Group Processes | 1 | 2018 | 226 | 0.030 |
Why?
|
Ethanol | 1 | 2023 | 1324 | 0.030 |
Why?
|
Anemia, Hemolytic | 1 | 2017 | 163 | 0.030 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2760 | 0.030 |
Why?
|
Cerebral Veins | 1 | 2017 | 157 | 0.030 |
Why?
|
Angiography | 1 | 2022 | 1599 | 0.030 |
Why?
|
Hemostatics | 1 | 2019 | 241 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 2017 | 206 | 0.030 |
Why?
|
Embolectomy | 1 | 2016 | 129 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29588 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15835 | 0.030 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2016 | 86 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2329 | 0.030 |
Why?
|
Incidental Findings | 1 | 2020 | 697 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 2019 | 673 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10498 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2017 | 534 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 824 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 822 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6758 | 0.030 |
Why?
|
Disease Management | 1 | 2005 | 2504 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1088 | 0.030 |
Why?
|
Pulmonary Medicine | 1 | 2016 | 221 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 916 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2018 | 875 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 546 | 0.030 |
Why?
|
Neural Pathways | 1 | 2024 | 3057 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7954 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10075 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 814 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 3489 | 0.030 |
Why?
|
Hematology | 1 | 2016 | 244 | 0.030 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 415 | 0.030 |
Why?
|
Splenectomy | 1 | 2013 | 391 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2296 | 0.020 |
Why?
|
Hospitals, General | 1 | 2016 | 798 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1183 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1665 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2017 | 1071 | 0.020 |
Why?
|
Critical Care | 1 | 2024 | 2697 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 161 | 0.020 |
Why?
|
Autoantibodies | 1 | 2020 | 2123 | 0.020 |
Why?
|
Health Care Costs | 1 | 2024 | 3243 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 931 | 0.020 |
Why?
|
Vision Disorders | 1 | 2017 | 1088 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 29858 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1742 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2016 | 722 | 0.020 |
Why?
|
Medicine | 1 | 2017 | 940 | 0.020 |
Why?
|
Mutation | 3 | 2021 | 30044 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9333 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10764 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168388 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 39974 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6478 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5310 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3057 | 0.020 |
Why?
|
Exercise | 1 | 2024 | 5883 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3268 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 611 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12710 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1551 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6571 | 0.020 |
Why?
|
Physicians | 1 | 2024 | 4591 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 787 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22124 | 0.020 |
Why?
|
Cardiology | 1 | 2016 | 1667 | 0.020 |
Why?
|
Child | 2 | 2024 | 80156 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9639 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15719 | 0.010 |
Why?
|
Necrosis | 1 | 2008 | 1605 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2013 | 2163 | 0.010 |
Why?
|
Bone Marrow | 1 | 2013 | 2909 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12059 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11098 | 0.010 |
Why?
|
Brain | 2 | 2020 | 27103 | 0.010 |
Why?
|
Radiology | 1 | 2016 | 2113 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1385 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13355 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6473 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10760 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59196 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2811 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2170 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 2534 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7999 | 0.010 |
Why?
|
Societies, Medical | 1 | 2008 | 3905 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 3929 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36430 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 6178 | 0.010 |
Why?
|